Back to Search Start Over

Successful Childbirth During Satralizumab Treatment in Neuromyelitis Optica Spectrum Disorder.

Successful Childbirth During Satralizumab Treatment in Neuromyelitis Optica Spectrum Disorder.

Authors :
Nakashima S
Hao A
Uchio N
Matsumoto H
Source :
Cureus [Cureus] 2024 Feb 27; Vol. 16 (2), pp. e55010. Date of Electronic Publication: 2024 Feb 27 (Print Publication: 2024).
Publication Year :
2024

Abstract

A 40-year-old woman with neuromyelitis optica spectrum disorder (NMOSD) and anti-aquaporin 4 antibodies suffered three NMOSD episodes between 35 and 37 years of age. Despite treatment with prednisolone and azathioprine, her condition repeatedly relapsed. We introduced satralizumab, targeting interleukin-6 receptors, which stabilized her condition. At the age of 38, she became pregnant and delivered a healthy baby at 38 weeks. Post delivery, both mother and child stayed healthy with no NMOSD relapses. This case illustrates the efficacy and safety of satralizumab in managing NMOSD, especially for women in their reproductive years who are planning pregnancy.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright © 2024, Nakashima et al.)

Details

Language :
English
ISSN :
2168-8184
Volume :
16
Issue :
2
Database :
MEDLINE
Journal :
Cureus
Publication Type :
Report
Accession number :
38550492
Full Text :
https://doi.org/10.7759/cureus.55010